Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunzhang Yang

Showing results (11-20 of 102) with videos related to

Pageof 11
Sort By:
Essays in Biochemistry|May 25, 2022
IDH mutation and cancer stem cellYang Zhang, Yang Liu, Fengchao Lang, et al.
Neuro-Oncology Advances|July 18, 2024
Pathways to hypermutation in high-grade gliomas: Mechanisms, syndromes, and opportunities for immunotherapyTuesday Haynes, Mark R Gilbert, Kevin Breen, et al.
Cell & Bioscience|June 12, 2019
Brusatol, an NRF2 inhibitor for future cancer therapeuticSabrina J Cai, Yang Liu, Sue Han, et al.
Pharmacology & Therapeutics|June 25, 2021
Genotoxic therapy and resistance mechanism in gliomasFengchao Lang, Yang Liu, Fu-Ju Chou, et al.
Cells|September 28, 2021
D-2-Hydroxyglutarate in Glioma BiologyFu-Ju Chou, Yang Liu, Fengchao Lang, et al.
Frontiers in Endocrinology|October 7, 2021
Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body ParagangliomaFengchao Lang, Abhishek Jha, Leah Meuter, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 1, 2009
Cystic fibrosis transmembrane conductance regulator expression in human spinal and sympathetic gangliaNa Niu, Jie Zhang, Yong Guo, et al.
Pharmacology & Therapeutics|April 6, 2018
Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapyYanxin Lu, Yang Liu, Ying Pang, et al.
Plos One|April 3, 2014
Maotai ameliorates diethylnitrosamine-initiated hepatocellular carcinoma formation in miceXu Yi, Li Long, Chunzhang Yang, et al.
Cell Reports|January 16, 2013
Proteostasis modulators prolong missense VHL protein activity and halt tumor progressionChunzhang Yang, Kristin Huntoon, Alexander Ksendzovsky, et al.
Pageof 11

Showing results (11-20 of 102) with videos related to

Sort By:
Pageof 11
Essays in Biochemistry|May 25, 2022
IDH mutation and cancer stem cellYang Zhang, Yang Liu, Fengchao Lang, et al.
Neuro-Oncology Advances|July 18, 2024
Pathways to hypermutation in high-grade gliomas: Mechanisms, syndromes, and opportunities for immunotherapyTuesday Haynes, Mark R Gilbert, Kevin Breen, et al.
Cell & Bioscience|June 12, 2019
Brusatol, an NRF2 inhibitor for future cancer therapeuticSabrina J Cai, Yang Liu, Sue Han, et al.
Pharmacology & Therapeutics|June 25, 2021
Genotoxic therapy and resistance mechanism in gliomasFengchao Lang, Yang Liu, Fu-Ju Chou, et al.
Cells|September 28, 2021
D-2-Hydroxyglutarate in Glioma BiologyFu-Ju Chou, Yang Liu, Fengchao Lang, et al.
Frontiers in Endocrinology|October 7, 2021
Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body ParagangliomaFengchao Lang, Abhishek Jha, Leah Meuter, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 1, 2009
Cystic fibrosis transmembrane conductance regulator expression in human spinal and sympathetic gangliaNa Niu, Jie Zhang, Yong Guo, et al.
Pharmacology & Therapeutics|April 6, 2018
Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapyYanxin Lu, Yang Liu, Ying Pang, et al.
Plos One|April 3, 2014
Maotai ameliorates diethylnitrosamine-initiated hepatocellular carcinoma formation in miceXu Yi, Li Long, Chunzhang Yang, et al.
Cell Reports|January 16, 2013
Proteostasis modulators prolong missense VHL protein activity and halt tumor progressionChunzhang Yang, Kristin Huntoon, Alexander Ksendzovsky, et al.
Pageof 11